Navigation Links
Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform
Date:11/2/2007

and developer of the Angio-Seal(TM) Vascular Closure Device, which is licensed to St. Jude Medical, Inc.

Cautionary Note for Forward-Looking Statements

This press release contains forward-looking statements that reflect the Company's current expectations about its prospects and opportunities. The Company has tried to identify these forward looking statements by using words such as "expect," "anticipate," "estimate," "plan," "will," "forecast," "believe," or similar expressions, but these words are not the exclusive means for identifying such statements. The Company cautions that a number of risks, uncertainties, and other important factors could cause the Company's actual results to differ materially from those in the forward-looking statements including, without limitation, the Company's success in launching its endovascular products into the marketplace, the Company's dependence on three major customers (St. Jude Medical, Arthrex and Orthovita) and their success in selling Kensey Nash related products in the marketplace, the impact of product recalls and other manufacturing issues, and competition from other technologies, among other important risks. For a more detailed discussion of these and other factors, please see the Company's SEC filings, including the disclosure under "Risk Factors" in those filings. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.


'/>"/>
SOURCE Kensey Nash Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. PM announces a new health care order for India
2. Ramdoss Announces Introduction of RCH-II
3. Britain Announces Third Transfusion Related Mad Cow Case
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. PowderMed Announces Needle-Less Flu Vaccine
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...ire/ -- The general membership of the Medical,Adv...dividuals at their Annual,Awards Dinner to be hel...k. A,Lifetime Achievement Award will also be give...vertising Hall of Fame are: , Ronald Pantello, ...osition,at Sudler & Hennessey. In 1980 he lef...
(Date:11/21/2008)...s do not cause genetic damage that can lead to dis...) -- Two popular medications for treating attentio...se genetic damage linked to an increased risk for ...y, done by researchers at Duke University Medical ...ters a previous one that reported biomarkers assoc...
(Date:11/21/2008)...e/ -- In a statewide survey, 33 physicians credent...ry at Presbyterian Hospital of Dallas were honored..." Super Doctors ." , , Each year, the publi...l Media, Inc. to survey more than 38,000 medical p... you needed medical care, which doctor would you c...
(Date:11/21/2008)...ewswire-FirstCall/ -- Symmetry Medical Inc. (NYSE:...ts to the global orthopedic device industry and ot... Moore, President and Chief Executive Officer, and...ancial Officer, are scheduled to present at the 20...The New York Palace Hotel on Wednesday, December 3...
Breaking Medicine News(10 mins):Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 2Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 3Health News:ADHD Medications Don't Pose Cancer Risk 2Health News:Annual List of 'Super Doctors' Features 33 Texas Institute for Surgery Physicians 2
... early test of the first vaccine against hepatitis...kens many Asians and can spread// to soldiers or o... made from moth cells infected with an engineered ...palese Army soldiers who took all three doses. How...
...esota permission to use state money on all varieti... bar human cloning.// The amended proposal cleare...pment Committee on a 12-7 vote. Scientists are st... to find treatments or cures for spinal cord injur...
...apanese patients looking for organ transplantation...ent of foreign patients in Chinese hospitals, more...y and not sure of receiving transplants in their h... nation where surgeries are less costly and quicke...
...ken over as the Director General of Army's Medical...ent Medical College, Nagpur he was commissioned in...ning MD in Radio Diagnosis from Pune University in...ion Oncology from the prestigious Tata Memorial Ho...
Other Medicine News:
(Date:11/20/2008)...November 20 Arpida (SWX:...ugs Advisory Committee of the,U.S. Food and Drug ...,approval of intravenous iclaprim, an antibiotic ...ients with complicated skin and skin structure inf...cillin-resistant Staphylococcus,aureus (MRSA). ,...
(Date:11/20/2008)...0 Bionovo, Inc.,(Nasdaq...lts from the Phase 1B,clinical trial of their lea...ancer, BZL101, at the Society for Integrative Onco... Georgia. The Company,s oral presentation was sel...nted as a part of the Best of the,SIO Session on ...
(Date:11/20/2008)... Radius Health ("Radius") announced...n to its second institutional financing round, inc... and the total amount raised since the company,s i...onal investors participated in the financing, led ... Capital, The Wellcome Trust, HealthCare Ventures,...
(Date:11/20/2008)...e-FirstCall/ -- PAREXEL International Corporation ...cal services provider, today announced that it has...ory consulting and clinical research capabilities.... has locations throughout five important biopharma...ude Argentina, Brazil, Chile, and Mexico. This exp...
Breaking Medicine Technology:Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 3Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4Emageon Receives Best in KLAS Cardiology PACS Award 15216 1Emageon Receives Best in KLAS Cardiology PACS Award 15216 2QMed Inc Reports Year End and Fourth Quarter Results 15213 1QMed Inc Reports Year End and Fourth Quarter Results 15213 2QMed Inc Reports Year End and Fourth Quarter Results 15213 3QMed Inc Reports Year End and Fourth Quarter Results 15213 4QMed Inc Reports Year End and Fourth Quarter Results 15213 5QMed Inc Reports Year End and Fourth Quarter Results 15213 6QMed Inc Reports Year End and Fourth Quarter Results 15213 7Best Practice Database 3A Complimentary Excerpt of Scientific Publications Strategy Study 15210 1Best Practice Database 3A Complimentary Excerpt of Scientific Publications Strategy Study 15210 2NCPA Statement on Californias Delay of E Pedigree Implementation 15207 1NCPA Statement on Californias Delay of E Pedigree Implementation 15207 2
...LAINATE, Italy - July 4, 2007 - Cosmo Pharmaceutic...inary results from its,phase II/III study with CB-...ea. CB-01-11 is a broad spectrum, semi-synthetic,a...t form. Through,the use of Cosmo,s MMX(tm) technol... colon, bacteria in the gastro intestinal tract,th...
...is weeks issue of Science,researchers from the Na...(NIEHS) and Umeö University in Sweden report ...hat an enzyme called,DNA polymerase epsilon plays ...st and perhaps even humans. , The study places us ...nome instability that underlie certain environment...
Other Medicine Technology:Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III,Data with Rifamycin MMX in Infectious Diarrhea 2NIEHS Researchers Identify Enzyme Critical in DNA Replication 2NIEHS Researchers Identify Enzyme Critical in DNA Replication 3
...ries is a national reference laboratory and a worl... development. ARUP offers an extensive test menu o...cal and anatomic pathology. Owned by the Universit... than half of the nation's university teaching hos...
...ries is a national reference laboratory and a worl... development. ARUP offers an extensive test menu o...cal and anatomic pathology. Owned by the Universit... than half of the nation's university teaching hos...
...ries is a national reference laboratory and a worl... development. ARUP offers an extensive test menu o...cal and anatomic pathology. Owned by the Universit... than half of the nation's university teaching hos...
...ries is a national reference laboratory and a worl... development. ARUP offers an extensive test menu o...cal and anatomic pathology. Owned by the Universit... than half of the nation's university teaching hos...
Medicine Products: